Source comparison
MOTS-C Versus Direct AMPK Activators
One useful way to locate MOTS-C is to compare it with the pharmacological AMPK activators whose biology is far better understood. The comparison is instructive not because MOTS-C competes clinically with these agents — it does not, having no approved use — but
This comparison does not assign a generated winner or score.
- One useful way to locate MOTS-C is to compare it with the pharmacological AMPK activators whose biology is far better understood. The comparison is instructive not because MOTS-C competes clinically with these agents — it does not, having no approved use — but because it clarifies what kind of AMPK activator MOTS-C is and how much less is known about it.
- Metformin
- Indirect: inhibits mitochondrial complex I, raises AMP:ADP, plus AMPK-independent actions
- Approved drug, decades of human data (type 2 diabetes)
- AICAR (acadesine)
- Direct AMP mimetic: its monophosphate (ZMP) binds the AMPK γ subunit
- Long-used research tool; investigational; prohibited in sport
- A-769662 / MK-8722 (direct activators)
- Bind the AMPK β-subunit ADaM site, activate the enzyme directly
- Research/preclinical pharmacology tools
- Salicylate
- Binds the ADaM site (aspirin metabolite)
- Human exposure via aspirin; AMPK effect characterized
- MOTS-C
- Indirect: inhibits folate cycle → AICAR/ZMP accumulation → AMPK; plus AMPK-dependent nuclear signaling
- Preclinical; no approved use; prohibited in sport19
- The table exposes a telling point: MOTS-C’s proposed mechanism is mechanistically adjacent to AICAR, since both ultimately rely on ZMP-mediated occupancy of the AMPK γ site. In a sense MOTS-C is an endogenous way of generating an AICAR-like signal from within one-carbon metabolism, rather than supplying the mimetic directly.15 That is genuinely novel and biologically interesting. But note the right-hand column: the agents above MOTS-C either are approved medicines with extensive human data (metformin), or are decades-old characterized research tools (AICAR, A-769662, salicylate). MOTS-C sits at the bottom precisely because, despite an appealing mechanism, its human evidence is minimal and its regulatory status is that of an unapproved experimental substance that is banned in competitive sport under the metabolic-modulator/AMPK-activator category of the WADA list.9
- A further contrast is worth drawing. Metformin’s AMPK engagement, for all its clinical importance, turned out to be only part of its mechanism, and pinning down which of its effects are truly AMPK-dependent took years of careful work. That history is a cautionary tale for MOTS-C: a molecule can genuinely activate AMPK and still have its overall physiology poorly captured by the AMPK story alone. Expect the MOTS-C picture to grow more complicated, not simpler, as it is studied.